Genky DrugStores Co., Ltd. (JP:9267)
:9267
Want to see JP:9267 full AI Analyst Report?
Top Page
Genky DrugStores Co., Ltd.
(9267)
Select Model
Select Model
Rating:62Neutral
Price Target:
¥3,731.00
▼(-24.78% Downside)
Action:Downgraded
Date:05/02/26
The score is supported by solid profitability and balance-sheet strength, but is meaningfully constrained by negative free cash flow and clearly bearish technical signals (price below major moving averages with weak MACD/RSI/Stoch). Valuation is neutral-to-slightly supportive with a moderate P/E, though the dividend yield is minimal.
Positive Factors
Stable retail drugstore model
Genky's core store-based retail model centers on essential health, pharmacy, and daily-consumption items that drive repeat purchases. This product mix and physical footprint support predictable sales and customer loyalty, making revenue streams resilient to short-term volatility and durable over months.
Negative Factors
Negative free cash flow
Despite operating cash flow strength, a sharp decline into negative free cash flow signals capex or working-capital stress that reduces internal funding capacity. Persisting FCF deficits could force reliance on external financing, constrain reinvestment or dividend flexibility and weaken long-term financial optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable retail drugstore model
Genky's core store-based retail model centers on essential health, pharmacy, and daily-consumption items that drive repeat purchases. This product mix and physical footprint support predictable sales and customer loyalty, making revenue streams resilient to short-term volatility and durable over months.
Read all positive factors
Genky DrugStores Co., Ltd. (9267) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥111.25B
Dividend Yield0.25%
Average Volume (3M)62.69K
Price to Earnings (P/E)18.9
Beta (1Y)0.44
Revenue Growth9.94%
EPS Growth15.75%
CountryJP
Employees1,661
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)232.48
Shares Outstanding31,031,569
10 Day Avg. Volume60,060
30 Day Avg. Volume62,690
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.17
Price to Sales (P/S)0.58
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)260.7
Revenue Forecast (FY)¥222.15B
Genky DrugStores Co., Ltd. Business Overview & Revenue Model
Company Description
Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan....
How the Company Makes Money
Genky DrugStores primarily makes money through retail sales in its physical stores. Its core revenue stream is the sale of over-the-counter medicines and other health/beauty-related items (e.g., personal care products). In addition, it generates r...
Genky DrugStores Co., Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 200.79B | 184.86B | 169.06B | 154.64B | 142.38B |
| Gross Profit | 35.09B | 32.53B | 29.90B | 26.68B | 26.55B |
| EBITDA | 15.95B | 14.58B | 11.66B | 10.27B | 10.35B |
| Net Income | 7.07B | 6.32B | 4.76B | 4.42B | 4.83B |
Balance Sheet | |||||
| Total Assets | 128.27B | 114.84B | 106.92B | 97.64B | 91.28B |
| Cash, Cash Equivalents and Short-Term Investments | 6.22B | 5.90B | 5.33B | 5.44B | 7.91B |
| Total Debt | 34.37B | 30.65B | 32.35B | 30.96B | 28.56B |
| Total Liabilities | 74.84B | 68.15B | 66.23B | 61.40B | 59.11B |
| Stockholders Equity | 53.43B | 46.68B | 40.68B | 36.23B | 32.17B |
Cash Flow | |||||
| Free Cash Flow | -2.50B | 2.98B | -1.12B | -4.39B | 3.26B |
| Operating Cash Flow | 12.60B | 13.26B | 8.77B | 6.08B | 12.08B |
| Investing Cash Flow | -15.62B | -10.63B | -9.74B | -10.59B | -8.83B |
| Financing Cash Flow | 3.35B | -2.06B | 854.00M | 2.04B | -1.95B |
Genky DrugStores Co., Ltd. Technical Analysis
Negative
4960.00
Price Trends
4162.60
Negative
4479.14
Negative
4552.33
Negative
Market Momentum
-10.67
Negative
48.20
Neutral
28.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Negative. The current price of 4960 is above the 20-day moving average (MA) of 4012.50, above the 50-day MA of 4162.60, and above the 200-day MA of 4552.33, indicating a neutral trend. The MACD of -10.67 indicates Negative momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 28.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9267.
Genky DrugStores Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥439.63B | 14.05 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥368.12B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥580.69B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
62 Neutral | ¥111.25B | 18.86 | ― | 0.25% | 9.94% | 15.75% | |
62 Neutral | ¥947.68B | 19.41 | ― | 1.72% | ― | ― | |
60 Neutral | ¥499.01B | 16.97 | ― | 0.93% | 6.74% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9267
Genky DrugStores Co., Ltd.
3,620.00
55.87
1.57%
JP:9989
Sundrug Co
3,760.00
-641.52
-14.57%
JP:7649
Sugi Holdings Co
3,081.00
-12.40
-0.40%
JP:3391
TSURUHA Holdings
2,106.50
-90.57
-4.12%
JP:3349
COSMOS Pharmaceutical Corporation
6,269.00
-2,744.15
-30.45%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,850.00
322.32
9.14%
Genky DrugStores Co., Ltd. Corporate Events
Genky DrugStores Extends Regional Store Expansion While Sustaining Profit Growth
Apr 28, 2026
Genky DrugStores reported steady expansion of its store network and sales floor, increasing total outlets from 480 to 538 in fiscal 2026 while maintaining a focus on core regional markets. Revenue and gross profit continued to grow at high single&...
Genky DrugStores Lifts Nine-Month Profit, Confirms Dividend and Growth Outlook
Apr 28, 2026
Genky DrugStores reported consolidated net sales of ¥161.7 billion for the nine months ended March 20, 2026, up 9.7% year on year, with operating income rising 17.3% to ¥8.0 billion and net income attributable to owners of the parent cli...
Genky DrugStores Extends Sales Growth as Store Network Expands to 516
Apr 28, 2026
Genky DrugStores reported robust April performance for the fiscal year ending June 2026, with all-store net sales up 9.4% year on year and existing-store sales up 1.7%. Customer traffic at existing stores rose 2.1% while spending per customer edge...
Genky DrugStores Extends Sales Growth as Store Network Reaches 510
Mar 31, 2026
Genky DrugStores reported solid year-on-year sales growth for March in both all stores and existing stores, supported by rising customer traffic despite slightly weaker spending per customer. The company continues to standardize its network, openi...
Genky DrugStores Extends Store Network as Same-Store Sales Level Off in February
Feb 27, 2026
Genky DrugStores reported continued top-line growth in February for all stores, with net sales up year on year and total store count rising to 503 as it opened three new standardized regular stores and recorded no closures. Existing stores saw fla...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.